4.1.1.28 2-mercaptoethanol enhances activity 4227 4.1.1.28 amantadine drug acting on glutamatergic receptor type enhances AAAD activity 691888 4.1.1.28 Benzene stimulates 4210 4.1.1.28 budipine drug acting on glutamatergic receptor type enhances AAAD activity 691888 4.1.1.28 cGMPdependent protein kinase Ialpha phosphorylates and activates neuronal AAAD, maximal increase of activity is obtained at about 100-175 units during a 10 min incubation at 30°C 715979 4.1.1.28 chloroform stimulates 4210 4.1.1.28 clonidine drug acting on alpha adrenergic receptor type enhances AAAD activity 691888 4.1.1.28 clozapine drug acting on serotonerg receptor type enhances AAAD activity 691888 4.1.1.28 clozapine enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist 691888 4.1.1.28 dextrometorphan drug acting on glutamatergic receptor type enhances AAAD activity 691888 4.1.1.28 dithiothreitol enhances activity 4227 4.1.1.28 flupenthixol enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist 691888 4.1.1.28 flupenthixol enhances activity in rat striatum 691888 4.1.1.28 forskolin intracerebroventricularly injection enhances the enzyme activity, a response, that can be blocked by selective inhibitors of protein kinase A 691888 4.1.1.28 glutathione enhances activity 4227 4.1.1.28 haloperidol enhanced AAAD activity in the striatum by acute and chronic treatment with the D2-like receptor antagonist 691888 4.1.1.28 ketanserin drug acting on serotonerg receptor type enhances AAAD activity 691888 4.1.1.28 L-745,870 enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist 691888 4.1.1.28 L-Dopa L-DOPA treatment (20-200 microM) increases the levels of dopamine by 226%-504% after 3-6 h of treatment and enhances the activities of tyrosine hydroxylase and aromatic L-amino acid decarboxylase 692194 4.1.1.28 light increases AAAD activity in retina 691888 4.1.1.28 mecamylamine drug acting on cholinerg receptor type enhances AAAD activity 691888 4.1.1.28 memantine drug acting on glutamatergic receptor type enhances AAAD activity 691888 4.1.1.28 metergoline drug acting on serotonerg receptor type enhances AAAD activity 691888 4.1.1.28 MK-801 drug acting on glutamatergic receptor type enhances AAAD activity 691888 4.1.1.28 additional information A conserved AP-1 (JNK activated transcription factor complex) binding upstream of the DDC transcription start site is necessary to induce DDC transcription 694157 4.1.1.28 additional information activation in vivo occurs in response to the acute action of physiological stimuli, drugs that act at neurotransmitter receptors, or modulation of the activity of endogenous kinases and phospatases 691888 4.1.1.28 additional information aseptic wounding of larvae or adults does not lead to DDC transcriptional induction, unlike in embryos where DDC activity at the edge of the wound contributes to the formation of a melanin clot 694157 4.1.1.28 additional information DDC is overexpressed, at the mRNA level, in the specimens from prostate cancer patients, in comparison to those from benign prostate hyperplasia patients. High expression levels of DDC are found more frequently in high Gleason's score tumors as well as in advanced stage patients. 691846 4.1.1.28 additional information high expression of DDC in blood and bone marrow corresponds to metastatic neuroblastoma at diagnosis, residual disease, and poor outcome 692661 4.1.1.28 additional information injection of Escherichia coli increases enzyme activity 651068 4.1.1.28 additional information pyridoxal 5'-phosphate deficiency reduces AADC activity 705265 4.1.1.28 additional information relative to obtained dose of Adeno-associated virus type 2 including human AADC gene, high dose-dependent levels of cDNA are detected 694283 4.1.1.28 additional information the early activation of AAAD is followed by a late, longer lasting (hours) response, which is accompanied by an increase of mRNA and protein 691888 4.1.1.28 additional information Transcription of the dopa decarboxylase gene is induced in response to gram-negative and gram-positive septic injury, but not aseptic wounding. Ddc transcripts are detectible within 2 h and remain high for several hours following infection with either gram-negative (Escherichia coli) or gram-positive (Staphylococcus aureus) bacteria. Ddc transcription depends on a previously uncharacterized member of the p38 mitogen-activated protein kinase family, p38c 694157 4.1.1.28 O2 required 4201 4.1.1.28 phencyclidine drug acting on glutamatergic receptor type enhances AAAD activity 691888 4.1.1.28 phorbol-12,13-myristic acid intracerebroventricularly injection enhances the enzyme activity, a response, that can be blocked by selective inhibitors of protein kinase A 691888 4.1.1.28 pimozide enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist 691888 4.1.1.28 protein kinase A phosphorylates and activates AAAD in vitro 691888 4.1.1.28 pyridoxal 5'-phosphate increases enzyme activity greatly 650450 4.1.1.28 pyridoxal 5'-phosphate stimulated by addition of excess pyridoxal phosphate 650868 4.1.1.28 pyridoxal 5'-phosphate stimulates decarboxylation of DOPA 653346 4.1.1.28 remoxipride enhanced AAAD activity in the striatum by acute treatment with the D2-like receptor antagonist 691888 4.1.1.28 SCH 23390 enhanced AAAD activity in the striatum by acute and chronic treatment with the D1-like receptor antagonist 691888 4.1.1.28 SKF 38393 enhanced AAAD activity in the striatum by chronic treatment with the D1-like receptor agonist 691888 4.1.1.28 spiperone drug acting on serotonerg receptor type enhances AAAD activity 691888 4.1.1.28 spiperone enhanced AAAD activity in the striatum by acute and chronic treatment with the D2-like receptor antagonist 691888 4.1.1.28 sulpiride enhanced AAAD activity by in the striatum by acute and chronic treatment with the D2-like receptor antagonist 691888 4.1.1.28 Way 100635 drug acting on serotonerg receptor type enhances AAAD activity 691888